We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 25, 2021

Anti–PD-1 and Anti–CTLA-4 Therapy in Operable NSCLC

Nature Medicine


Additional Info

Nature Medicine
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial
Nat. Med. 2021 Feb 18;[EPub Ahead of Print], T Cascone, WN William, A Weissferdt, CH Leung, HY Lin, A Pataer, MCB Godoy, BW Carter, L Federico, A Reuben, MAW Khan, H Dejima, A Francisco-Cruz, ER Parra, LM Solis, J Fujimoto, HT Tran, N Kalhor, FV Fossella, FE Mott, AS Tsao, G Blumenschein, X Le, J Zhang, F Skoulidis, JM Kurie, M Altan, C Lu, BS Glisson, LA Byers, YY Elamin, RJ Mehran, DC Rice, GL Walsh, WL Hofstetter, JA Roth, MB Antonoff, H Kadara, C Haymaker, C Bernatchez, NJ Ajami, RR Jenq, P Sharma, JP Allison, A Futreal, JA Wargo, II Wistuba, SG Swisher, JJ Lee, DL Gibbons, AA Vaporciyan, JV Heymach, B Sepesi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading